ANDA 75117, held by Concordia Pharms Inc. Prednisolone Sodium Phosphate.
As of Nov 16, 2026, ANDA 75117 (Orapred), held by Concordia Pharms Inc, was first approved by FDA on Dec 14, 2000, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 14, 2000 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| OrapredEQ 15MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ยท solution;oral | Prednisolone Sodium Phosphate | Discontinued |
| Jun 16, 2005 | Supplement 12Labeling | Approved | None posted |
| Nov 7, 2002 | Supplement 6Manufacturing | Approved | None posted |
| May 8, 2002 | Supplement 5Manufacturing | Approved | None posted |
| Aug 28, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Aug 28, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Jun 25, 2001 | Supplement 2Manufacturing | Approved | None posted |
| Mar 28, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Dec 14, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters